ProQuest Investments, a healthcare-dedicated venture capital firm, announced the closing of ProQuest Investments IV, L.P., a $425 million venture capital fund. The closing of ProQuest Investments IV brings funds under management at ProQuest Investments to approximately $900 million.
"We are privileged to be supported by a distinguished group of limited partners who are headquartered around the world. The strong demand for participation in this fund by both our returning and new limited partners led to a significant over-subscription. We were gratified to receive a commitment far exceeding our target raise but held to our promise to cap the fund at $425 million," commented Pasquale DeAngelis, CFO and Administrative Partner of ProQuest Investments.
ProQuest is a healthcare-dedicated venture capital firm with approximately $900 million under management in four funds. With offices in Princeton, NJ, San Diego, CA, and Montreal, Canada, ProQuest invests across North America in biopharmaceutical companies with clearly differentiated products or potential products that address significant unmet medical needs. Since its inception in 1998, ProQuest's twelve investment professionals have invested in over 40 emerging healthcare companies.
For more information on ProQuest portfolio companies and the firm, please visit: www.proquestvc.com